Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models

Accumulating evidence suggests AKT1 and DRD2-AKT-GSK3 signaling involvement in schizophrenia. AKT1 activity is also required for lithium, a GSK3 inhibitor, to modulate mood-related behaviors. Notably, GSK3 inhibitor significantly alleviates behavioral deficits in Akt1(−/−) female mice, whereas typic...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Da-Zhong, Chang, Chia-Yuan, Huang, Tsung-Ren, Studer, Vincent, Wang, Tsu-Wei, Lai, Wen-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971245/
https://www.ncbi.nlm.nih.gov/pubmed/31959776
http://dx.doi.org/10.1038/s41598-019-57340-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971245/
https://www.ncbi.nlm.nih.gov/pubmed/31959776
http://dx.doi.org/10.1038/s41598-019-57340-8

Ejemplares similares